Efficacy

Efficacy of Enhertu (fam-trastuzumab deruxtecan-nxki) in Breast Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted therapy drug that has shown significant efficacy in the treatment of certain types of breast cancer. Specifically, it is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Enhertu is a conjugated monoclonal antibody that combines trastuzumab with a cytotoxic chemotherapy agent, allowing for the direct delivery of chemotherapy to cancer cells overexpressing the HER2 protein. Clinical trials have demonstrated that Enhertu significantly improves progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer compared to standard treatments.

Efficacy of Phesgo (pertuzumab, trastuzumab, and hyaluronidase) in Breast Cancer

Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with the enzyme hyaluronidase, which is used to enhance the subcutaneous delivery of the drugs. This combination is indicated for use in patients with HER2-positive early breast cancer, where it is used in the neoadjuvant (pre-surgery) setting, and for metastatic cases as well. Pertuzumab and trastuzumab target the HER2 receptor, a protein that promotes the growth of cancer cells. In clinical trials, Phesgo has been shown to be effective in reducing the size of tumors before surgery and improving survival rates in the metastatic setting when used in combination with chemotherapy.

The efficacy of Phesgo in early breast cancer was demonstrated in a pivotal clinical trial where it was compared with the intravenous formulations of trastuzumab and pertuzumab. The results showed that Phesgo was non-inferior to the intravenous formulations in terms of efficacy, with similar rates of pathologic complete response (pCR), which is a measure of the absence of invasive cancer in the breast and lymph nodes following treatment. In the metastatic setting, Phesgo, in combination with chemotherapy, has shown to improve progression-free survival, offering a convenient subcutaneous administration route that can be administered in a shorter amount of time compared to intravenous infusions.

Both Enhertu and Phesgo represent significant advancements in the treatment of HER2-positive breast cancer, offering patients new options that can improve outcomes and, in the case of Phesgo, potentially offer a more convenient administration method. It is important for healthcare providers to assess the suitability of these treatments for their patients based on individual clinical profiles and to monitor for potential side effects associated with these targeted therapies.